Home / Business and Economy / Spero Therapeutics Strikes $1.1B Deal with Innovent Biologics
Spero Therapeutics Strikes $1.1B Deal with Innovent Biologics
14 Jul
Summary
- Spero Therapeutics to develop and commercialize Innovent's experimental drug.
- The deal outside Greater China is valued at up to $1.1 billion.
- The focus is on innovative treatments for autoimmune diseases.
Spero Therapeutics has acquired crucial licensing rights from Innovent Biologics for an experimental autoimmune disease treatment. This strategic agreement, effective as of Tuesday, July 14, 2026, pertains to territories outside of Greater China.
The comprehensive deal is potentially worth up to approximately $1.1 billion. It represents a significant expansion for Spero Therapeutics in its efforts to develop novel therapies. The focus of this collaboration is on addressing unmet needs in the autoimmune disease sector.
Innovent Biologics will benefit from this partnership by seeing its promising experimental treatment gain broader development and commercialization potential. Both companies are poised to leverage their expertise to advance this therapeutic candidate.
